



Annual Report 2025 | Building the Foundation

Content

1	Executive Summary.....	2
2	About Yamicc.....	4
3	2025: Building the Foundation.....	5
3.1	Strategic Objective 1 Building the Organisation.....	5
3.2	Strategic Objective 2 Shaping the Platform Vision.....	6
3.3	Strategic Objective 3 Building the Ecosystem.....	6
3.4	Strategic Objective 4 Strengthening Visibility.....	7
4	Key Learnings.....	8
5	Governance & Organisation.....	10
6	Financial Review.....	13
7	Risks & Risk Management.....	15
8	Looking Ahead to 2026.....	17
8.1	Priority 1 High-performing organization.....	17
8.2	Priority 2 Platform POC program.....	18
8.3	Priority 3 Platform Adoption.....	18
8.4	Priority 4 Funding.....	19
8.5	Priority 5 Sustainable business model.....	19
8.6	Financial Outlook 2026.....	20
8.7	Concluding Perspective.....	22
9	Stakeholders & Societal Value.....	23
10	Financial Report.....	25
11	Independent Auditor’s Review Report.....	36

1 Executive Summary

A Year of Building the Foundation

The year 2025 marked an important milestone in the development of Yamicc. What began as a mission-driven initiative continued to evolve into a structured organisation with a clear vision, growing ecosystem and solid governance grounds.

Yamicc was founded from the belief that patients with rare cancers deserve faster access to effective treatments and that collaboration, supported by innovative technology, can play an important role in accelerating clinical research. Throughout 2025, the organisation focused on transforming this ambition into a practical and sustainable basis for future impact.

Rather than pursuing rapid growth, Yamicc concentrated on four strategic priorities: building the organisational capabilities required for future growth, shaping the vision for the Yamicc Platform, developing a strong ecosystem of stakeholders and increasing visibility within the clinical research community.

Key achievements in 2025

- Strengthened Yamicc's governance through the establishment of a Supervisory Board and Advisory Board;
- Expanded a growing network of clinicians, researchers, hospitals, technology partners and supporters;
- Further developed and validated the vision for the Yamicc Platform through extensive stakeholder engagement;
- Established Erasmus MC as Yamicc's first strategic clinical collaboration partner and supported the development of the ReDiReCCT-GB trial initiative;
- Organised the first edition of Yamicc Live, bringing together stakeholders from across the clinical research ecosystem;
- Developed and demonstrated the first technical platform concept, providing initial validation of the platform vision.

Key learnings

Several important insights emerged throughout the year. Yamicc learned that meaningful progress is achieved through collaboration rather than ownership, that sustainable impact requires a sustainable funding model, that technology must be driven by clinical needs, and that trust and adoption are just as important as innovation itself. These learnings helped refine Yamicc's role within the clinical research ecosystem and continue to guide the organisation's strategic direction.

Financial highlights

Yamicc closed the year with total income of €1.6 million and a positive result of €346 thousand. The foundation maintained a healthy financial position, enabling continued investment in its mission and providing a solid basis for future activities.

Looking ahead to 2026

Building on the progress achieved in 2025, Yamicc enters 2026 with a clear strategic direction and a growing network of partners and supporters.

The focus for the coming year will shift from exploration towards execution. Key priorities include the further development and validation of the Yamicc Platform, strengthening adoption through strategic collaborations, expanding funding opportunities and exploring a sustainable long-term business model. The Board is confident that the capabilities, partnerships and governance structures established during 2025 provide a strong basis for the next phase of Yamicc's development and mission.

"2025 was a year in which a shared ambition began to take shape. We are grateful to everyone who contributed to building the foundation for what comes next."

The Board of Yamicc



Roald Kruit
Chair



Bert van der Schelde
Board Treasurer &
Governance



Clemens Dirven
Secretary for
Medical affairs

2 About Yamicc

Mission

Yamicc is committed to initiating, facilitating and coordinating large-scale collaboration to accelerate the development of effective treatments for cancer, with a specific focus on rare cancers, supported by innovative information and data technology.

Patients with rare cancers often face limited treatment options due to small patient populations, fragmented data and the complexity of conducting clinical research across institutions. Yamicc was founded from the conviction that these challenges can only be addressed through collaboration, shared infrastructure and the responsible use of technology.

Vision

Yamicc envisions a future in which clinical research is faster, more affordable, more efficient and more impactful, enabling effective treatments to reach patients sooner.

In this future, hospitals, researchers, life sciences organisations and technology partners work together through connected and interoperable infrastructures. Data can be reused responsibly, clinical trials can be executed more efficiently across institutions, and innovative technologies such as artificial intelligence can help reduce administrative burden while improving quality and outcomes.

What we do

Yamicc acts as an independent, mission-driven facilitator of collaboration within the clinical research ecosystem.

We bring together hospitals, researchers, patient representatives, technology partners and other stakeholders to address common challenges in clinical research. Through the development of the Yamicc Platform and its surrounding ecosystem, we aim to simplify and accelerate the design, execution and scaling of clinical trials.

Our role is not to replace existing organisations or infrastructures, but to connect and strengthen them. By combining collaboration, data-driven innovation and responsible technology, Yamicc helps create the conditions needed to accelerate research and improve outcomes for patients.

3 2025: Building the Foundation

The year 2025 marked a defining chapter in the development of Yamicc. What started as a mission-driven initiative evolved into a more structured organisation, laying the foundations for future execution and impact.

The key achievements of 2025 can be grouped into four strategic themes.

3.1 Strategic Objective 1 | Building the Organisation

The year 2025 was primarily focused on establishing the capabilities required to deliver Yamicc's long-term mission. As a young organisation, much of the work centred on exploring the challenges within clinical research, validating the need for a different approach, and establishing the relationships, governance structures and expertise required to create meaningful impact in the years ahead.

A major milestone during 2025 was the strengthening of Yamicc's governance structure. A Supervisory Board was established to provide independent oversight and strategic guidance, while an Advisory Board was formed to bring together expertise from the medical, scientific and technology domains. The involvement of highly respected experts and leaders from across the ecosystem strengthened both the credibility and strategic direction of the organisation.

Yamicc also strengthened its operational capabilities through the expansion of its core team. As the organisation evolved from a founder-led initiative towards a more structured operating model, specialised expertise was added across organisational leadership, legal & compliance, and platform architecture. Together, these capabilities created a strong basis for future platform development, ecosystem collaboration and organisational growth.

Alongside the core team, Yamicc continued to attract support from a growing network of volunteers and supporters who contributed their knowledge, experience and time to help advance the Yamicc's mission. This growing engagement served as an important validation of both the relevance of the challenge Yamicc seeks to address and the collaborative approach it promotes.

By the end of 2025, Yamicc had established the governance, capabilities, relationships and strategic direction required to move into the next phase of development. These achievements positioned the organisation to focus on platform development, adoption and measurable impact in 2026.

3.2 Strategic Objective 2 | Shaping the Platform Vision

A second major focus area for Yamicc in 2025 was the development and validation of its platform vision. While the organisation was founded on the belief that technology can play an important role in accelerating clinical research, many questions remained regarding the most effective way to create value for hospitals, researchers and patients.

Throughout the year, Yamicc worked with clinicians, researchers and technology partners to better understand the practical barriers that slow down clinical research. This process helped refine the platform vision and led to an important insight: meaningful impact would come not from replacing existing systems, but from enabling interoperability, standardisation and collaboration across the clinical research ecosystem.

To translate the vision into something tangible, Yamicc developed and validated an initial platform concept and paper prototype. These early explorations helped structure discussions with partners, test assumptions and identify opportunities for future development. Towards the end of the year, this work culminated in the development of an initial technical demonstration, providing the first validation that the underlying concepts could be translated into a practical technology solution.

While the platform vision continued to evolve beyond 2025, the work undertaken during the year established a clear strategic direction and significantly reduced uncertainty around the role technology could play in supporting faster, more connected and more efficient clinical research. These insights provided the basis for the next phase of platform development and execution in 2026.

3.3 Strategic Objective 3 | Building the Ecosystem

Collaboration is at the heart of Yamicc's mission. As a newly established organisation, one of the most important objectives in 2025 was therefore to better understand the clinical research ecosystem and build meaningful relationships with the organisations and individuals working within it.

Throughout the year, Yamicc engaged with a broad range of stakeholders, including clinicians, researchers, university medical centres, patient advocates, funding organisations, technology companies and other organisations active in the field of clinical research. These conversations provided valuable insights into the challenges, opportunities and realities of conducting research, particularly within the context of rare cancers.

A particularly important relationship during 2025 was the collaboration with Erasmus MC, which became Yamicc's first strategic clinical collaboration partner. Through its engagement with Erasmus MC Yamicc gained a deeper understanding of clinical workflows, operational challenges and opportunities to improve research processes through technology, standardisation and collaboration.

Rather than focusing on rapid expansion, Yamicc adopted a listening and learning approach. A recurring theme across stakeholder discussions was that many organisations face similar challenges, yet solutions are often developed in isolation. This reinforced Yamicc's belief that greater interoperability, knowledge sharing and standardisation can accelerate research and improve outcomes for patients. By the end of 2025, Yamicc had established a growing network of hospitals, research institutions, technology partners and funding organisations that would form the basis for future collaborations and pilot initiatives.

3.4 Strategic Objective 4 | Strengthening Visibility

As a newly established organisation, building visibility and credibility was an important priority in 2025. Through its website, digital channels, events and stakeholder engagement activities, Yamicc sought to increase awareness of its mission and strengthen connections across the clinical research ecosystem.

An important milestone was the launch of a renewed Yamicc website, providing a stronger platform to communicate the organisation's mission, activities and vision. In parallel, Yamicc increased its presence through digital channels and stakeholder engagement, helping to attract new supporters, volunteers and partners who shared an interest in advancing clinical research through collaboration and innovation.

A highlight of the year was the organisation of the first edition of Yamicc Live. This event brought together clinicians, hospitals, technology partners, supporters and other stakeholders from across the ecosystem to exchange ideas, strengthen relationships and explore opportunities for collaboration. The event marked an important moment in Yamicc's development, providing a platform to share its vision, showcase early progress and engage the broader community around its mission. During the event, important milestones were celebrated, including the formalisation of strategic collaborations and the presentation of Yamicc's first platform demonstration.

The growing interest from stakeholders throughout the year reinforced the relevance of Yamicc's mission and the need for greater collaboration within the clinical research ecosystem. By the end of 2025, Yamicc had established an initial presence within the community and positioned the organisation for broader engagement and visibility in the years ahead.

4 Key Learnings

Through conversations with stakeholders, the development of the platform vision and the exploration of the clinical research landscape, several important insights emerged that helped shape Yamicc's strategic direction.

Collaboration creates more value than ownership

One of the most important lessons from 2025 was that meaningful progress in clinical research is best achieved through collaboration rather than ownership. As Yamicc engaged with hospitals, researchers and technology partners, it became increasingly clear that many valuable initiatives, systems and data infrastructures already exist. Rather than creating parallel solutions, Yamicc can create greater impact by connecting stakeholders, enabling collaboration and strengthening existing ecosystems.

Standardisation and interoperability matter more than centralised data ownership

Throughout 2025, Yamicc further refined its view on the role data should play in accelerating clinical research. While many organisations initially associate innovation with the creation of new data platforms or repositories, Yamicc observed that valuable data sources and registries already exist across the healthcare and research ecosystem.

The challenge is often not the availability of data itself, but the ability to capture, structure, exchange and reuse data in a consistent and efficient manner. This reinforced Yamicc's belief that its role is not to become a central data owner, but rather to facilitate standardised data flows, interoperability and responsible data processing across existing systems and organisations. This insight continues to shape the development of the Yamicc Platform and its position within the broader clinical research ecosystem.

Sustainable impact requires a sustainable funding model

The exploration of grants, subsidies and donations provided valuable opportunities, but also highlighted the complexity and unpredictability of traditional funding mechanisms. Funding processes often depend on external stakeholders, involve long lead times and can limit organisational flexibility. As a result, Yamicc recognised the importance of exploring a long-term, mission-aligned and sustainable revenue model alongside grants and donations.

Technology should be driven by clinical needs

Throughout the year, Yamicc learned that successful innovation starts with a deep understanding of the practical challenges faced by clinicians, researchers and hospitals. The development of the platform vision therefore evolved from a technology-led perspective towards a needs-driven approach, focused on solving real-world challenges within clinical research. This insight remains a guiding principle for future platform development.

Trust and adoption are critical success factors

Beyond technology, Yamicc learned that trust, governance and adoption play a crucial role in enabling change within clinical research. Hospitals and researchers operate in a highly regulated and complex environment where credibility, transparency and compliance are essential. Building strong relationships, understanding stakeholder needs and aligning with existing governance structures proved just as important as technological innovation itself.

Together, these learnings helped refine Yamicc's role within the clinical research ecosystem and provided valuable guidance for the organisation's priorities and strategic direction in 2026 and beyond.

5 Governance & Organisation

Governance Structure

Yamicc is organised as an independent non-profit foundation (stichting) and operates under a governance model designed to support transparency, accountability and long-term mission alignment.

The foundation is governed by a Board (Bestuur), which is responsible for the overall management, strategic direction and fulfilment of Yamicc's statutory objectives. The Supervisory Board (Raad van Toezicht) provides independent oversight of the Board, monitors organisational performance and advises on strategic developments.

During 2025, Yamicc strengthened its governance framework through the establishment of a Supervisory Board and the further involvement of advisors from medical, scientific and technology domains. Together, these governance bodies provide independent oversight, specialist expertise and strategic guidance in support of Yamicc's mission.

Table 1. Governance Bodies as of 31 December 2025

Governance Body	Role
Board (Bestuur)	Responsible for the management, strategic direction and statutory responsibilities of the foundation
Supervisory Board (Raad van Toezicht)	Provides independent oversight and advises the Board on strategic and governance matters
Advisory Board	Provides medical, scientific and technology expertise to support Yamicc's mission and development

Table 2. Board Members

Name	Position
Roald Kruit	Chair
Bert van der Schelde	Board Treasurer & Governance
Clemens Dirven	Secretary for Medical affairs

Table 3. Supervisory Board

Name	Position
Hans van Leeuwen	Member
Wiro Niessen	Member
Chris Polman	Chair

Organisation

At the end of 2025, Yamicc operated with a deliberately lean organisational structure, combining a small core team with a broader network of advisors, volunteers and specialised external expertise.

This approach enabled the organisation to remain agile while continuing to build the knowledge, relationships and capabilities required to advance its mission. Rather than pursuing rapid organisational growth, Yamicc focused on selectively adding expertise in areas that were critical to the further development of the organisation, its governance framework and its platform vision.

During the year, Yamicc strengthened its operational capabilities through the expansion of its core team. Dedicated expertise was added in organisational leadership, legal and compliance, information security, and platform architecture through the appointment of a General Manager, a Head of Legal & Information Security, and an Integration Architect. These additions marked an important step in Yamicc's transition from a founder-led initiative towards a more structured organisation capable of supporting platform development, ecosystem collaboration and future growth.

In parallel, Yamicc further strengthened its governance and advisory structures. Alongside the Board and Supervisory Board, an Advisory Board was established consisting of eight senior experts from the clinical, scientific, technology and funding domains. The Advisory Board provides strategic advice, domain expertise and access to relevant networks, helping to strengthen both the quality and credibility of the organisation's activities.

By the end of 2025, Yamicc's organisational structure consisted of a core team of four employees, supported by three Board members, three Supervisory Board members, eight Advisory Board members and a network of six active volunteers. Together, these groups contributed expertise across domains including governance, clinical research, technology, legal and compliance, information security, funding, human resources, marketing, recruitment and strategic development.

In addition, Yamicc benefited from the contributions of specialised external experts and consultants who provided support in areas where additional expertise was required. This flexible operating model enabled the organisation to access high-quality knowledge and capabilities while maintaining a prudent and efficient use of resources.

By the end of 2025, Yamicc had established an organisational structure that combined focused leadership, independent oversight, specialised expertise and broad ecosystem engagement. Together, this provides a strong basis for the next phase of platform development, adoption and organisational growth.

Remuneration

Yamicc is committed to ensuring that its resources are used responsibly and in line with its mission.

Members of the Board and Supervisory Board perform their duties on an unpaid basis and do not receive remuneration for their governance responsibilities. Where applicable, expenses incurred in the performance of these duties may be reimbursed in accordance with policies.

Throughout 2025, Yamicc operated with a combination of employees, volunteers and specialised external experts. Employees were compensated in accordance with their employment agreements, while volunteers contributed their time and expertise without financial compensation.

This approach reflects Yamicc's commitment to maintaining a lean and mission-driven organisation while ensuring access to the expertise required to support its development and objectives.

6 Financial Review

2025 represented Yamicc's first reporting period and was characterised by investing in the capabilities required to deliver the organisation's long-term mission. During the year, Yamicc focused on building its governance structure, developing and validating its platform vision, expanding its ecosystem and supporting the initiation of clinical research activities.

The foundation closed the year with total income of € 1,605,468 and total expenditure of € 1,265,652, resulting in an operating surplus of € 339,816. Financial income of € 6,358 increased the result for the year to € 346,174. This positive result was added to the Other reserve, strengthening the organisation's financial position and supporting future activities

Table 4. Key Financial Highlights

Financial Indicator	2025
Total Income	€ 1,605,468
Total expenditure	€ 1,265,652
Result for the year	€ 346,174
Other reserves	€ 346,174
Cash and cash equivalents (year-end)	€ 625,868

Income

Income during 2025 consisted primarily of donations and contributions received in support of Yamicc's mission. These funds enabled the organisation to invest in the development of its governance framework, organisational capabilities, platform vision and ecosystem activities.

As a young foundation, Yamicc remained largely dependent on a limited number of significant funding sources during 2025. While this support enabled substantial progress during the year, the organisation recognises the importance of further diversifying its funding base over time to strengthen long-term sustainability.

Expenditure

Expenditure during 2025 was primarily directed towards activities supporting Yamicc's mission and strategic objectives. This included investments in organisational development, governance, technology exploration and validation, ecosystem engagement and the support of clinical research initiatives of Erasmus MC Foundation.

The foundation maintained a lean operating model throughout the year by combining a small core organisation with the contributions of volunteers, advisors and specialised external expertise. This enabled Yamicc to access critical knowledge and capabilities while maintaining careful stewardship of available resources.

Financial Position

In line with prudent financial management, the positive result for 2025 was added to the Other reserves. The reserves support the stability and continuity of the organisation and provides a financial buffer against future uncertainties.

At year-end, Yamicc held cash and cash equivalents of € 625,868, providing a solid basis for the execution of planned activities in 2026. The Board considers maintaining appropriate Reserves important in safeguarding the long-term sustainability of the foundation and its mission.

Outlook

While Yamicc's financial position at year-end was healthy, the organisation remains focused on securing sustainable funding for future growth and impact. In 2026, Yamicc will continue to explore a combination of grants, donations and mission-aligned revenue opportunities to support the further development of its platform and ecosystem.

Further details regarding the financial position, accounting policies and financial statements can be found in the accompanying 2025 Annual Accounts.

7 Risks & Risk Management

As a young and growing organisation, Yamicc recognises that achieving its mission involves navigating a range of uncertainties and risks. Throughout 2025, the Board regularly reviewed the key risks facing the foundation and took steps to strengthen governance, oversight and organisational resilience. The most significant risks identified at the end of 2025 are outlined below.

Funding and Financial Sustainability

As an early-stage non-profit organisation, Yamicc remained dependent on a limited number of funding sources during 2025. While this support enabled the organisation to make significant progress, long-term sustainability requires a broader and more diversified funding base.

To mitigate this risk, Yamicc continued to explore grants, donations and other funding opportunities while maintaining a prudent financial position and establishing a continuity reserve. In addition, the organisation explored access to supplementary financing through loan arrangements, providing additional flexibility to support its activities where required.

The Board continuously monitors Yamicc's financial position and funding outlook. To support the continuity assessment for the foreseeable future, a Letter of Comfort has been provided, confirming the intention to support the organisation should additional funding be required to meet its obligations and continue its mission.

Platform Development and Execution

The successful realisation of Yamicc's mission depends in part on the ability to translate the platform vision into practical solutions that create value for hospitals, researchers and patients. As the platform concept was still in an early stage of development at the end of 2025, uncertainty remained regarding future implementation and scalability.

To address this risk, Yamicc adopted an iterative approach focused on validation, stakeholder engagement and early technical exploration before committing to larger-scale investments.

Adoption and Ecosystem Engagement

The impact of Yamicc's platform vision depends on the willingness of stakeholders across the clinical research ecosystem to collaborate and adopt new ways of working. Differences in priorities, governance structures and organisational readiness may slow adoption and implementation.

Throughout 2025, Yamicc focused on building relationships, understanding stakeholder needs and involving ecosystem partners in the development of its vision and approach.

Organisational Capacity

As a relatively small organisation, Yamicc remained dependent on a limited number of key individuals and external experts. This created a risk related to organisational capacity and the ability to execute an ambitious program of activities.

To mitigate this risk, Yamicc continued to strengthen its governance structure, expand its network of volunteers and advisors, and gradually build the capabilities required for future growth. In addition, the organisation increased its focus on prioritisation and execution by concentrating resources on a smaller number of strategic objectives and reducing exploratory activities. This approach helps ensure that available capacity is directed towards initiatives with the greatest potential impact.

Risk Management Approach

Yamicc seeks to balance ambition with responsible governance. The foundation takes a proactive approach to identifying, monitoring and managing risks, with oversight provided by the Board and Supervisory Board.

While uncertainty is inherent to innovation and organisational development, Yamicc believes that the governance structures, financial discipline and collaborative approach established during 2025 provide a strong foundation for managing future risks and supporting sustainable growth.

8 Looking Ahead to 2026

The year 2025 marked an important phase in the development of Yamicc. During the year, focus lied on a refined vision, strengthened governance and organisational foundations, expanding its ecosystem, and validating the need for a new approach to accelerating clinical research.

The insights gained throughout 2025 have provided Yamicc with greater clarity regarding its role within the clinical research ecosystem and the opportunities to create impact through technology, collaboration and data-driven innovation.

To support the transition from exploration to execution, Yamicc will further strengthen its strategic planning and documentation framework in 2026. Building on the Annual Plan established at the end of 2025, the organisation will further translate its vision into a more concrete roadmap through the development of a strategic Whitepaper and Product Program Plan, creating alignment across its governance bodies, team members, ecosystem partners and other stakeholders.

Building on these learnings, 2026 will be a year of execution and validation. The organisation will focus on translating its vision into operational reality through the development of the Yamicc Platform, the expansion of strategic collaborations and the continued strengthening of the foundation. To guide this next phase, Yamicc has defined five strategic priorities for 2026.

8.1 Priority 1 | High-performing organization

As Yamicc continues to grow, organisational maturity becomes increasingly important. During 2026, the foundation will further strengthen its governance, operational processes and internal collaboration structures.

Key priorities include:

- Further development of the management team and organisational structure;
- Strengthening governance and decision-making processes;
- Continued development of compliance capabilities, including information security and quality management;
- Creating a scalable operating model that supports future growth.

The objective is to ensure that Yamicc has the organization required to deliver its mission sustainably and effectively.

8.2 Priority 2 | Platform POC program

A key focus for 2026 is the development and validation of the first version of the Yamicc Platform. Based on extensive discussions with hospitals, researchers and ecosystem partners, Yamicc has refined its platform vision towards a practical and scalable model that supports clinical research without replacing existing systems and processes.

The initial Proof-of-Concept program will focus on:

- Supporting clinical trial execution through integrated workflows and platform services;
- Developing the technical groundwork required for future scalability;
- Validating the platform in real-world research environments;
- Demonstrating operational efficiencies for researchers and participating centres.

To support successful execution, Yamicc will further strengthen the strategic and operational basis of the program. A strategic Whitepaper will be developed to document and communicate the long-term vision, guiding principles and rationale behind the Yamicc Platform. In parallel, a Product Program Plan will translate this vision into a concrete roadmap, defining the scope, priorities and deliverables of the initial platform development phase. Together, these documents will help ensure alignment across governance bodies, team members, ecosystem partners and other stakeholders. The platform is intended to serve as the foundation for future expansion and broader ecosystem adoption.

8.3 Priority 3 | Platform Adoption

Yamicc believes that sustainable adoption can only be achieved through close collaboration with leading research institutions and ecosystem partners. Rather than pursuing rapid scale, the organisation will focus on a limited number of strategic collaborations that enable the platform to be developed and validated in practice.

During 2026, Yamicc aims to:

- Deepen collaboration with a few selected key academic medical centres;
- Support live clinical research projects through the platform;
- Expand and formalize its network of technology and ecosystem partners;
- Record learnings and develop playbooks to support future expansion.

This approach is expected to create a strong foundation for long-term growth and impact.

8.4 Priority 4 | Funding

As an innovation-driven foundation operating in a highly specialised domain, access to sustainable funding remains a key priority. During 2026, Yamicc will continue to diversify its funding base through:

- Grant applications and public funding programs;
- Donations and philanthropic contributions;
- Strategic partnerships;
- Early validation of future platform-related revenue streams.

In addition, Yamicc will pilot a number of media and visibility initiatives aimed at increasing awareness of its mission among potential supporters and donors. These include participation in the Dutch Dragons podcast and selected publications and interviews, such as the ABN AMRO Financial Focus platform. The objective is to strengthen visibility, expand the organisation's network and assess the potential contribution of media exposure to future fundraising and philanthropic support. This balanced approach is intended to support both short-term continuity and long-term sustainability.

8.5 Priority 5 | Sustainable business model

The insights obtained throughout 2025 highlighted the importance of establishing a sustainable business model that enables Yamicc to maximise its societal impact while ensuring long-term continuity. In 2026, Yamicc will further explore and validate potential commercial models surrounding the platform, while safeguarding its mission-driven objectives.

Key areas of focus include:

- Conducting detailed market research and segmentation
- Develop a go to market approach
- Defining value propositions for different stakeholder groups;
- Exploring pricing and partnership models;
- Assessing opportunities for scalable platform services;
- Developing a long-term strategy that balances societal impact with financial sustainability.

8.6 Financial Outlook 2026

To support the execution of its strategic priorities, Yamicc has established a 2026 operating budget. The budget reflects the organisation's transition from exploration towards execution, with increased investments in platform development, ecosystem adoption and organisational capabilities.

Based on the current budget, Yamicc expects total income of approximately €530,000 and total expenditure of approximately €1.06 million, resulting in a planned deficit of €525,000. This deficit reflects deliberate investments in the development of the Yamicc Platform, organisational capacity and ecosystem growth.

Yamicc entered 2026 with cash and cash equivalents of €625,868, providing a solid basis for the execution of its planned activities during the year. The planned deficit will be funded from the reserves accumulated during 2025, allowing the foundation to invest in platform development and organisational growth while continuing to pursue additional funding opportunities. The organisation continues to actively pursue additional funding through grants, donations, strategic partnerships and the validation of mission-aligned revenue streams to support its long-term sustainability.

The Board continuously monitors the financial position of the foundation and periodically reviews funding requirements, expenditure levels and strategic priorities to ensure responsible stewardship of available resources and continuity of operations.

Table 5. Budget 2026

	Budget 2026	
Income		
Income from companies	-	
Income from individuals	€ 530,000	
Total Income		€ 530,000
Expenditure		
Spend on programmes	-	
Income recruitment cost	€ 206,780	
Management & administration cost	€ 849,801	
Total expenditure		€ 1,056,581
Balance before financial income & Expenditure		-€ 526,581
Financial Income / expenditure		€ 2,000
Balance of income & Expenditure		-€ 524,581
Bank balance 1 January 2026		€ 625,868
Movements 2026		-€ 528,293
Bank balance 31 December 2026		€ 97,575

8.7 Concluding Perspective

Yamicc enters 2026 with a clear strategic direction, a growing ecosystem of partners and an increasingly mature organisation.

The Board is confident that the foundations established during 2025 provide a strong basis for the next phase of Yamicc's development and mission. During 2026, the organisation will focus on validating its platform strategy in practice, strengthening adoption within the clinical research ecosystem and progressing towards a sustainable long-term operating model. Through these efforts, Yamicc aims to take the next step towards accelerating clinical research for patients with rare cancers.

9 Stakeholders & Societal Value

Yamicc was established to accelerate the development of effective treatments for patients with rare cancers. Achieving this mission requires collaboration across the entire clinical research ecosystem. Through its activities, platform development and ecosystem approach, Yamicc seeks to create value for a broad range of stakeholders while contributing to more efficient and impactful clinical research.

Patients and Patient Communities

Patients with rare cancers often face limited treatment options due to the small number of patients available for research and the challenges associated with collecting sufficient high-quality data. By helping researchers and hospitals collaborate more effectively and by supporting the generation of larger and more standardised datasets, Yamicc aims to contribute to more efficient clinical research and, ultimately, improved treatment opportunities for patients.

Hospitals and Research Centres

Hospitals and research centres play a central role in the generation of clinical research data. Through the development of the Yamicc Platform, Yamicc aims to reduce administrative burden and improve the efficiency of clinical trial execution through automation, artificial intelligence and integrated workflows. A key element of this approach is the integration of clinical research processes with existing hospital systems, data infrastructures and biobanks, enabling data to be captured, exchanged and reused more efficiently without creating additional fragmentation or duplicate data repositories. This approach is expected to create value in four important ways:

- Enabling more clinical research to be conducted within existing research budgets and capacity constraints;
- Supporting the standardisation and interoperability of research data across institutions, making collaboration and data aggregation easier;
- • Facilitating the responsible reuse of data through integration with existing data sources, registries and biobanks, helping researchers access larger and more complete datasets for clinical research;
- Creating incentives for data sharing by offering platform capabilities to participating centres while supporting research focused on rare cancers.

Researchers and Clinical Trial Teams

Researchers often operate within complex environments characterised by fragmented systems, manual processes and limited resources. Yamicc aims to support researchers through technology that simplifies study preparation, trial execution and collaboration across institutions.

By reducing repetitive administrative activities and improving access to standardised data, researchers can spend more time focusing on scientific questions and patient outcomes.

The Clinical Research Ecosystem

Throughout its development, Yamicc has increasingly recognised that the challenge is not the absence of data, but the difficulty of capturing, standardising and responsibly reusing data across organisations. Many valuable datasets already exist, yet differences in systems, processes and data formats often limit their broader use for research.

Yamicc therefore focuses on enabling interoperability and standardised data flows to integrate with existing data- and biobanks rather than creating another standalone data repository. By connecting existing stakeholders and infrastructures, the organisation aims to contribute to a more collaborative and scalable research ecosystem.

The ability to aggregate larger volumes of high-quality, standardised data is particularly important for rare cancer research, where individual institutions often do not have sufficient patient numbers to generate meaningful insights on their own.

Partners, Supporters and Society

Yamicc's mission can only be achieved through collaboration. The organisation therefore works closely with hospitals, researchers, technology partners, patient representatives, volunteers, advisors, donors and funding organisations. Together, these stakeholders contribute knowledge, expertise, resources and support that help accelerate progress towards a shared goal: improving the future of clinical research and increasing the chances of better outcomes for patients with rare cancers.

As Yamicc moves into its next phase of development, the organisation remains committed to creating societal value through collaboration, responsible innovation and the development of shared infrastructure that enables faster, more efficient and more impactful clinical research.

Was Signed
on behalf of the Board,

Rotterdam, 23 June 2026

R. Kruit

C.M.F. Dirven

B.F. van der Schelde

10 Financial Report

10.1 Balance sheet as at 31 December 2025 (after appropriation of result)

	31 December 2025			31 December 2025	
	€	€		€	€
ASSETS			EQUITY AND LIABILITIES		
Fixed assets			Reserves		
Tangible fixed assets		6,780	Other reserves		346,174
Current assets			Long-term liabilities		
Receivables and prepayments	347,447		Long-term project liabilities		227,618
Bank	<u>625,868</u>		Current liabilities		
		973,315	Creditors	8,150	
			Short-term project liabilities	353,225	
			Taxes and social security	18,952	
			Other liabilities & accruals	<u>25,976</u>	
					406,303
Total assets		<u>980,095</u>	Total equity and liabilities		<u>980,095</u>

10.2 Statement of Income and Expenditure 2025 (from 9 October 2024 until 31 December 2025)

	2025	
	€	€
Income		
Income from companies	1,605,137	
Income from Individuals	331	
Total Income		1,605,468
Expenditure		
Spend on programmes	812,637	
Donation recruitment costs	44,851	
Management and administration costs	408,163	
Total expenditure		1,265,652
Balance before financial income and expenditure		339,816
Financial income/expenditure		6,358
Balance of Income & Expenditure		346,174

The 2025 budget was drawn up halfway through the financial year and did not serve as the basis for management in 2025. For this reason, the 2025 budget has not been included in these annual accounts.

The balance of Income and Expenditure of € 346,174 is added to the Other Reserve.

10.3 Cash flow statement 2025 (from 9 October 2024 until 31 December 2025)

The cash flow statement has been prepared using the indirect method.

	2025	
	€	€
Cash Flow form operating activities		
Balance before financial income and expenditure	339,816	
<i>Adjustments for:</i>		
Depreciation fixed assets	558	
Movement of working capital:		
Movement of accounts receivable	-344,941	
Movement of programmes in progress	580,843	
Movement of short term liabilities	53,078	
		629,354
Interest received		3,852
Cash flow from operating activities		633,206
 Cash flow from investing activities		
Investments fixed assets	-	7,338
		-
Total cash flow		625,868
 Compilation bank		
	€	€
Bank per 9 October 2024		0
Movement of bank and bank equivalents		625,868
Bank per 31 December 2025		625,868

10.4 Notes to the financial statements

10.4.1 General

Activities

The objective of Stichting Yamicc is to initiate, facilitate, and coordinate large-scale collaboration to find effective treatments for rare types of cancer using innovative (information) technology.

The foundation's first financial year is an extended financial year and runs from 9 October 2024 until 31 December 2025.

Registered office, legal form and registration number at the Chamber of Commerce

Stichting Yamicc was established on 9 October 2024, and its location is at Westewagenstraat 60 in Rotterdam. The foundation is registered with the Chamber of Commerce under number 95190112.

Continuity assumption

Stichting Yamicc is a young foundation actively seeking funding opportunities. Funding for the coming 12 months has been secured by a letter of comfort from an external party up to a maximum of €1 million, corresponding to the forecast expenses until the end of June 2027.

10.4.2 General accounting principles for the preparation of the financial statements

The financial statements are drawn up in accordance with the generally accepted accounting principles in the Netherlands (Guideline 650 of the Dutch Accounting Standards Board, the guideline for fundraising institutions).

Valuation of assets and liabilities and determination of the result, is performed under the historical cost convention. Unless presented otherwise, assets and liabilities are presented at nominal value. Income and expenses are accounted for on accrual basis.

Profit is only included when realized on the balance sheet date. Losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

The financial statements are prepared in €.

10.4.3 Principles of valuation of assets and liabilities

Tangible fixed assets

Tangible fixed assets are presented at acquisition price less cumulative depreciation and, if applicable, less impairments in value. Depreciation is based on the estimated useful life and calculated as a fixed percentage of the acquisition price, taking into account any residual value. Depreciation is calculated from the date an asset comes into use. For IT equipment and inventory furnishings the life-cycle is five years.

Receivables and pre-payments

Receivables are recognized at nominal value less any provision of doubtful accounts. Pre-payments are recognized in the balance sheet at nominal value.

Bank

Cash and cash equivalents are recognised at nominal value.

Reserves

Reserves include the Other Reserve. Additions and withdrawals to/from the reserves are determined from the appropriation of the result.

Liabilities

The liabilities are recognized at nominal value. Project liabilities refer to all liabilities under agreements concluded with third parties.

Other assets and liabilities

These are stated at nominal value.

10.4.4 Accounting principles for the determination of the result

Income and Expenditure

Income and expenditure in the Statement of Income and Expenses are allocated to the period to which they relate.

Income is recognised in the period in which there is legal entitlement, any performance conditions attached to the income have been met, the amount can be quantified with reasonable accuracy and there is probability of receipt.

Unrestricted donations are accounted for as income in the earliest reporting period that they are received or committed to.

The result is determined as the difference between income generated by contributions and other sources, and the costs and other charges for the year.

Financial income/expenditure

Financial income and expenditure comprise interest income and expenditure on bank accounts and exchange differences during the current reporting period.

10.4.5 Principles for the preparation of the cash flow statement

The cash flow statement has been prepared using the indirect method.

The funds in the cash flow statement consist of cash and short-term debt to financial institutions. Cash flows in foreign currencies are converted at the exchange rate at balance sheet date. Exchange rate differences concerning finances are shown separately in the cash flow statement.

Income and expenses related to interest are included in the cash flow statement for operational activities.

10.5 Notes to the Balance Sheet per 31 December 2025

Tangible fixed assets € 6,780

The tangible fixed assets consist of purchased IT hardware for staff members. The purchase value was € 7,338 of which € 558 was depreciated. Depreciation rate is 20%.

	Computers
	€
Book value per 9 October 2024	-
Movements	
Investments	7,338
Depreciation	- 558
Book value 31 December 2025	<u><u>6,780</u></u>

Receivables and prepayments € 347,447

Specification:

	<u>31/12/2025</u>
	€
Receivable Roint4Good	270,137
Prepayments	72,800
Interest	2,506
Creditor (negative balance)	<u>2,004</u>
	<u>347,447</u>

Stichting Yamicc has signed a donation agreement with Roint4Good BV for a total amount of € 1,600,137. In 2025 € 1,330,000 was received by Stichting Yamicc, so € 270,137 is still to be received. This amount was received in March 2026.

In 2025 € 85,525 was paid to Koalitix BV for consultancy activities; € 72.800 of this amount had not been spend in 2025. This amount will be spend in 2026.

The accrued interest on the ABN Amro savings account is € 2,506 at the end of 2025.

Bank € 625,868

Specification:

	<u>31/12/2025</u>
	€
Savings account	613,852
Bank account	9,225
Credit cards	<u>2,791</u>
	625,868

The bank balances are at the free disposal of the foundation.

Reserves € 346,174

Specification, Other reserve:

	<u>31-12-2025</u>
	€
Book value per 9 October 2024	0
Addition 2025	<u>346,174</u>
Value per 31 December 2025	346,174

Project liabilities € 580,843 (long-term € 227,618, short-term € 353,225)

Stichting Yamicc committed in 2025 to fund the programme costs related to the ReDiReCCT programme of Erasmus MC Foundation. A total amount of € 231,794 was paid in 2025. The remaining € 580,843 will be paid in 4 installments. In 2026 € 353,225 will be paid and in 2027 € 227,618.

Creditors € 8,150

The creditors as per 31 December 2025 have been fully paid in January 2026.

Taxes and social security € 18,952

This concerns the taxes and contributions payable according to the payroll tax return for December 2025.

Other liabilities & accruals € 25,976

Specification:

	<u>31/12/2025</u>
	€
External auditor	12,000
Legal support December 2025	11,314
Staff expenses	1,100
Holidays	1,047
Tax advice December 2025	318
Other costs to be paid	197
	<u>25,976</u>

Contingent liabilities

In December 2025, Stichting Yamicc entered into an agreement with a third party valued at €37,374 including VAT for the provision of consultancy services in the first half of 2026 for the purpose of grant applications.

10.6 Notes to the statement of income and expenditure 2025

Income from companies € 1,605,137

Stichting Yamicc has signed a donation agreement with Roint4Good BV on 30 December 2024 for a total amount of € 1,600,137. In 2025 € 1,330,000 was received by the foundation, so € 270,137 is to be received per 31 December 2025. This amount was received in March 2026.

Another donation of € 5,000 was received in July 2025.

Income from individuals € 331

During 2025, €331 in donations were received from donors.

Expenditure € 1,265,652

	Total 2025	Categories		
		Spend on programmes	Income recruitment costs	Management and administration costs
	€	€	€	€
Programme support costs	812,637	812,637		
Personnel costs				
Salary costs	200,005		30,625	169,380
Social charges	29,693		6,688	23,004
Other personnel costs	16,609		2,899	13,710
	246,307			
Other costs				
IT support 2024+2025	68,381			68,381
Consultancy costs 2025	30,685			30,685
Legal costs	67,615			67,615
Tax advice	13,485			13,485
Auditor and admin costs	12,684			12,684
Office expenses	5,412			5,412
Events	4,639		4,639	
Other costs	3,011			3,011
Bank costs	238			238
Depreciation costs	558			558
	206,708			
	1,265,652	812,637	44,851	408,164

Spend on programmes € 812,637

In 2025, a donation agreement was concluded with the Erasmus MC Foundation. This donation is aimed at (a) promoting innovative scientific medical research, (b) supporting scientific research by young talented people during their studies, research and specialization, and (c) supporting activities that contribute to future-oriented treatments, care and well-being of patients.

A total of € 812,637 is being donated by the Yamicc Foundation. Of this amount, € 231,794 was paid in 2025; € 353,225 will be paid in 2026 and the remaining amount (€ 227,618) in 2027.

Personnel costs € 246,307

Specification:

	2025
	€
Salary costs	200,005
Social charges	29,693
Other personnel costs	16,609
	246,307

In addition to their monthly salary, employees receive 8% holiday allowance. The foundation does not have a thirteenth month salary or other bonus schemes.

The first employee started in January 2025, and by the end of 2025, 6 employees (5.1 FTEs) were employed by the foundation.

The number of FTEs averaged 2.05 in the book year.

The three board members receive no compensation for their work.

Financial income/expenditure € 6,358

€ 6,358 interest was received on the savings account in 2025.

Was Signed
on behalf of the Board,

Rotterdam, 23 June 2026

R. Kruit

C.M.F. Dirven

B.F. van der Schelde

Was Signed
on behalf of the Supervisory Board,

Rotterdam, 23 June 2026

C. H. Polman

W.J. Niessen

J.P.T.M. van Leeuwen

11 Independent Auditor's Review Report

INDEPENDENT AUDITOR'S REVIEW REPORT

OUR CONCLUSION

We have reviewed the financial statements for the year ended 31 December 2025 of Stichting Yamicc based in Rotterdam.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying financial statements do not give a true and fair view of the financial position of Stichting Yamicc as at 31 December 2025 and of its result for the year then ended in accordance with Dutch Directive 650 – the directive for fundraising institutions.

The financial statements comprise:

- the balance sheet as at 31 December 2025;
- the statement of income and expenditure for the year ended 31 December 2025; and
- the notes comprising a summary of the accounting policies and other explanatory information.

BASIS FOR OUR CONCLUSION

We conducted our review in accordance with Dutch law, including the Dutch Standard 2400 'Opdrachten tot het beoordelen van financiële overzichten' (engagements to review financial statements). A review of financial statements in accordance with the Dutch Standard 2400 is a limited assurance engagement. Our responsibilities under this standard are further described in the 'Our responsibilities for the review of the financial statements' section of our report.

We are independent of Stichting Yamicc in accordance with the Verordening inzake de onafhankelijkheid van accountants bij assurance-opdrachten (ViO, Code of Ethics for Professional Accountants, a regulation with respect to independence) and other relevant independence regulations in the Netherlands. Furthermore we have complied with the Verordening gedrags- en beroepsregels accountants (VGBA, Dutch Code of Ethics).

We believe the assurance evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

RESPONSIBILITIES OF MANAGEMENT AND THE SUPERVISORY BOARD FOR THE FINANCIAL STATEMENTS

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Part 9 of Book 2 of the Dutch Civil Code⁵. Furthermore, management is responsible for such internal control as it determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

The supervisory board is responsible for overseeing the foundation's financial reporting process.

OUR RESPONSIBILITIES FOR THE REVIEW OF THE FINANCIAL STATEMENTS

Our responsibility is to plan and perform the review in a manner that allows us to obtain sufficient and appropriate assurance evidence for our conclusion.

The level of assurance obtained in a review engagement is substantially less than the level of assurance obtained in an audit conducted in accordance with the Dutch Standards on Auditing. Accordingly, we do not express an audit opinion.

We have exercised professional judgement and have maintained professional scepticism throughout the review, in accordance with Dutch Standard 2400.

Our review included among others:

- Obtaining an understanding in the entity and its environment⁸ and the applicable financial reporting framework, in order to identify areas in the financial statements where material misstatements are likely to arise due to fraud or error, designing and performing procedures to address those areas, and obtaining assurance evidence that is sufficient and appropriate to provide a basis for our conclusion;
- Obtaining an understanding of the entity's accounting systems and accounting records and consider whether these generate data that is adequate for the purpose of performing the analytical procedures;
- Making inquiries of management and others within the entity;
- Applying analytical procedures with respect to information included in the financial statements;
- Obtaining assurance evidence that the financial statements agree with, or reconcile to, the entity's underlying accounting records;
- Evaluating the assurance evidence obtained;
- Considering the appropriateness of accounting policies used and considering whether the accounting estimates and related disclosures made by management appear reasonable;
- Considering the overall presentation, structure and content of the financial statements, including the disclosures; and
- Considering whether the financial statements and the related disclosures represent the underlying transactions and events in a manner that appears to give a true and fair view.

Was Signed,
Rotterdam, June 23, 2026

HLB Den Hartog
Accountants & Consultants

M. Haag AA